Aspirin-Guide is an innovative app developed by Digital Clinix LLC, in collaboration with researchers at Brigham and Women’s Hospital, Harvard Medical School. Designed for clinicians, this app assists in determining which patients are suitable candidates for low-dose aspirin (75 to 100 mg/d) in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). By carefully balancing the benefits of ASCVD prevention against the risks of gastrointestinal or other bleeding, Aspirin-Guide provides valuable guidance to healthcare professionals.

One of the standout features of Aspirin-Guide is its ability to calculate a 10-year cardiovascular disease risk score for patients, considering both heart disease and stroke. This risk score is based on the ACC/AHA ASCVD score, incorporating relevant patient-specific risk factors. Additionally, clinicians can easily email a summary of the decision-making process directly to the patient, ensuring clear communication and shared decision-making.

It's worth noting that the app acknowledges the limitations of research on aspirin in primary prevention for individuals younger than age 50 or older than age 70. However, for patients within the appropriate age range, Aspirin-Guide proves to be an invaluable resource in implementing clinical guidelines for aspirin use in primary prevention.